MECAMYLAMINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mecamylamine Hydrochloride, and when can generic versions of Mecamylamine Hydrochloride launch?
Mecamylamine Hydrochloride is a drug marketed by Lgm Pharma and is included in one NDA.
The generic ingredient in MECAMYLAMINE HYDROCHLORIDE is mecamylamine hydrochloride. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the mecamylamine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mecamylamine Hydrochloride
A generic version of MECAMYLAMINE HYDROCHLORIDE was approved as mecamylamine hydrochloride by LGM PHARMA on March 19th, 2013.
Summary for MECAMYLAMINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 80 |
Clinical Trials: | 30 |
Patent Applications: | 490 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MECAMYLAMINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for MECAMYLAMINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Vanderbilt University Medical Center | Early Phase 1 |
Wayne State University | Phase 4 |
AstraZeneca | Phase 2 |
Pharmacology for MECAMYLAMINE HYDROCHLORIDE
Drug Class | Autonomic Ganglionic Blocker |
Physiological Effect | Decreased Autonomic Ganglionic Activity |
Medical Subject Heading (MeSH) Categories for MECAMYLAMINE HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for MECAMYLAMINE HYDROCHLORIDE
US Patents and Regulatory Information for MECAMYLAMINE HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lgm Pharma | MECAMYLAMINE HYDROCHLORIDE | mecamylamine hydrochloride | TABLET;ORAL | 204054-001 | Mar 19, 2013 | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |